GI Dynamics (ASX:GID) said last week in a regulatory filing that it fired chief medical officer Dr. David Maggs “for cause.” The Lexington, Mass.-based medical device company did not otherwise elaborate on the reason for Maggs’s departure, which was effective June 18, according to the filing. Maggs joined GI Dynamics in April 2013 to oversee the clinical […]
Histogenics
Histogenics sets range for $60m IPO
Histogenics set the per-share price range on its forthcoming initial public offering at $13 to $15 per share.
That puts the mid-point for the nearly 4.3 million-share offering at just under $60 million.
Histogenics files for $65m IPO
Histogenics filed for an initial public offering, aiming to raise up to $65 million as it begins Phase III testing of its knee cartilage product NeoCart.
The regenerative medicine company plans to list its shares on the NASDAQ exchange under the symbol HSGX.
JenaValve taps ex-AtriCure chief Drachman for CEO | Personnel Moves
Veran medical adds former Stryker CFO Hartman to board | Personnel Moves
Histogenics appoints a new CEO | Personnel Moves
Histogenics has a new face in the corner office with the appointment of Peter Greenleaf, an AstraZeneca veteran favored by the board for his experience moving products toward commercialization.
The company has its eyes on an end-stage pivotal trial for NeoCart, a device that uses patients’ own cells to regenerate knee cartilage.
UPDATE: Histogenics CEO on $49M funding round
Histogenics said it raised another $49 million for its regenerative cartilage treatments, as it proceeds with a clinical trial for its NeoCart treatment and pursues CE Mark approval for its VeriCart system.
The round was led by Sofinnova Ventures and including backing from new investors Split Rock Partners, BioMed Ventures and FinTech GIMV Fund. Prior backers ProChon Holdings BV, Altima Partners, Foundation Medical Partners, Inflection Point Capital and Boston Millennia Partners also kicked in.
Histogenics drums up $49M for NeoCart trial
Histogenics said it raised another $49 million for its regenerative cartilage treatments, as it proceeds with a clinical trial for its NeoCart treatment and pursues CE Mark approval for its VeriCart system.
The round was led by Sofinnova Ventures and including backing from new investors Split Rock Partners, BioMed Ventures and FinTech GIMV Fund. Prior backers ProChon Holdings BV, Altima Partners, Foundation Medical Partners, Inflection Point Capital and Boston Millennia Partners also kicked in.
Whistleblowing doctor fired from Northwestern University | Personnel Moves
A Northwestern University cardiologist who sparked a federal investigation into a fellow physician for alleged misconduct was fired after being denied tenure.
Dr. Nalini Rajamannan, who was an associate professor of medicine at the university, believes she was fired for providing evidence to federal investigators and for challenging the university’s star surgeon.
DeVivo takes over the corner office at AngioDynamics | Personnel Moves
AngioDynamics Inc. (NSDQ:ANGO) named a replacement for former CEO Jan Keltjens, who left suddenly in June, tapping Joseph DeVivo for the corner office.
The Latham, N.Y.-based oncology device company also revealed the resignation of senior vice president of business development Lynda Wallace, according to SEC filings.
Histogenics hires Dr. Michael Lewis and Peter Hamiltion to lead NeoCart in Phase III
WALTHAM, Mass.–(BUSINESS WIRE)–Regenerative medicine company Histogenics Corporation appoints Michael Lewis, M.D. to CMO and Peter Hamilton to VP of Manufacturing & Production to support Phase 3 development of NeoCart.